Enanta Pharmaceuticals (ENTA) Non-Current Assets (2012 - 2026)
Enanta Pharmaceuticals posted quarterly Non-Current Assets of $136.3 million for Q1 2026, up 70.08% year-on-year from $80.1 million in Q1 2025, and up 4.18% on a QoQ basis from $130.8 million in Q4 2025.
Enanta Pharmaceuticals (ENTA) has 15 years of Non-Current Assets data on file, last reported at $136.3 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets rose 70.08% year-over-year to $136.3 million; the trailing twelve-month figure through Mar 2026 stood at $421.8 million (up 20.64% YoY), and the FY2025 full-year result was $76.4 million, down 0.53% from the prior year.
- Non-Current Assets for Q1 2026 stood at $136.3 million, up from $130.8 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $136.3 million in Q1 2026 and bottomed at $38.2 million in Q4 2023.
- The 5-year median for Non-Current Assets is $72.2 million (2022), against an average of $75.2 million.
- The widest annual swing landed in 2022, when Non-Current Assets tumbled 46.82%; it then surged 140.32% in 2024.
- A 5-year view of Non-Current Assets shows it stood at $63.8 million in 2022, then plunged by 40.16% to $38.2 million in 2023, then jumped by 110.75% to $80.5 million in 2024, then soared by 62.51% to $130.8 million in 2025, then increased by 4.18% to $136.3 million in 2026.
- The last three Non-Current Assets figures came in at $136.3 million (Q1 2026), $130.8 million (Q4 2025), and $76.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - | 136.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 136.29 Mn |
| Dec 31, 2025 | 130.82 Mn |
| Sep 30, 2025 | 76.40 Mn |
| Jun 30, 2025 | 78.32 Mn |
| Mar 31, 2025 | 80.13 Mn |
| Dec 31, 2024 | 80.50 Mn |
| Sep 30, 2024 | 76.80 Mn |
| Jun 30, 2024 | 112.24 Mn |
| Mar 31, 2024 | 62.53 Mn |
| Dec 31, 2023 | 38.20 Mn |
| Sep 30, 2023 | 39.48 Mn |
| Jun 30, 2023 | 46.70 Mn |
| Mar 31, 2023 | 55.31 Mn |
| Dec 31, 2022 | 63.83 Mn |
| Sep 30, 2022 | 63.70 Mn |
| Jun 30, 2022 | 72.18 Mn |
| Mar 31, 2022 | 64.95 Mn |
| Dec 31, 2021 | 113.64 Mn |
| Sep 30, 2021 | 119.77 Mn |
| Jun 30, 2021 | 129.28 Mn |
| Mar 31, 2021 | 39.55 Mn |
| Dec 31, 2020 | 35.07 Mn |
| Sep 30, 2020 | 49.30 Mn |
| Jun 30, 2020 | 98.32 Mn |
| Mar 31, 2020 | 110.79 Mn |
| Dec 31, 2019 | 70.47 Mn |
| Sep 30, 2019 | 87.98 Mn |
| Jun 30, 2019 | 22.22 Mn |
| Mar 31, 2019 | 37.74 Mn |
| Dec 31, 2018 | 30.91 Mn |
| Sep 30, 2018 | 33.84 Mn |
| Jun 30, 2018 | 39.19 Mn |
| Mar 31, 2018 | 48.98 Mn |
| Dec 31, 2017 | 93.09 Mn |
| Sep 30, 2017 | 88.82 Mn |
| Jun 30, 2017 | 69.72 Mn |
| Mar 31, 2017 | 88.37 Mn |
| Dec 31, 2016 | 54.31 Mn |
| Sep 30, 2016 | 49.12 Mn |
| Jun 30, 2016 | 40.14 Mn |
| Mar 31, 2016 | 38.93 Mn |
| Dec 31, 2015 | 69.36 Mn |
| Sep 30, 2015 | 75.37 Mn |
| Jun 30, 2015 | 65.13 Mn |
| Mar 31, 2015 | 68.10 Mn |
| Dec 31, 2014 | 30.33 Mn |
| Sep 30, 2014 | 47.44 Mn |
| Jun 30, 2014 | 47.84 Mn |
| Mar 31, 2014 | 9.00 Mn |
| Dec 31, 2013 | 15.78 Mn |
| Sep 30, 2013 | 12.26 Mn |
| Jun 30, 2013 | 21.81 Mn |
| Mar 31, 2013 | 13.96 Mn |
| Sep 30, 2012 | 4.85 Mn |